Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 975 participants.

Also called NCT01368536

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 975 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01368536
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01368536. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2013-03-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Acronym
VALENCIA
Condition
Hypertension
Condition
Stage 2 Hypertension
Condition
Diabetes
Intervention (Drug)
Valturna
Intervention (Drug)
Amlodipine
Intervention (Drug)
Chlorthalidone
Intervention (Drug)
Placebo of Valturna Tablet
Intervention (Drug)
Placebo Capsule
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01368536
Content hash
91fad5ba8c5739393433dab957ab735d663f226791ca0dc69c478f1659b619d8